Pierre Legault - Aug 5, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, as Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Aug 5, 2022
Transactions value $
-$331,062
Form type
4
Date filed
8/9/2022, 04:05 PM
Previous filing
Feb 3, 2022
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $96.3K +10K +31.25% $9.63 42K Aug 5, 2022 Direct
transaction SNDX Common Stock Sale -$230K -10K -23.81% $23.02 32K Aug 5, 2022 Direct F1, F2
transaction SNDX Common Stock Options Exercise $125K +14K +43.75% $8.93 46K Aug 5, 2022 Direct
transaction SNDX Common Stock Sale -$322K -14K -30.43% $23.02 32K Aug 5, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -10K -100% $0.00* 0 Aug 5, 2022 Common Stock 10K $9.63 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -14K -100% $0.00* 0 Aug 5, 2022 Common Stock 14K $8.93 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 39,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $23.00 to $23.12
F3 This option is fully vested.